U.S. FDA approves AbbVie's drug for Parkinson's disease
The drug tavapadon, which AbbVie gained access to through its $8.7 billion acquisition of Cerevel Therapeutics in 2023, comes as a once-a-day pill
On Friday, September 25, 2026, the U.S. Food and Drug Administration announced its approval of AbbVie's treatment for Parkinson's disease in adults. The drug, called tavapadon, is available as a once-daily pill under the brand name Juvmo. Parkinson's is a long-term brain condition that affects movement control, leading to symptoms such as tremors, stiffness, and balance issues.
Approximately 11 million people worldwide suffer from the disease. Juvmo functions by replicating dopamine, a crucial brain chemical that diminishes in individuals with Parkinson's. The FDA's approval was based on data from AbbVie's late-stage trial program, which demonstrated that the drug alleviated symptoms in patients with the disease.
Reported side effects in the trials included nausea, dizziness, and headaches. AbbVie has not commented on the drug's launch and pricing. Analysts from Citi had previously anticipated the launch in the third quarter of 2026, but noted that adoption would likely be slow as discussions regarding the drug's Medicare coverage were ongoing.
Citi also projected that AbbVie would target over $5 billion in combined sales of the Parkinson's disease treatment.
Written by urgent.news from The Hindu - Sci-Tech's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
